Diagnostyka S.A (DIA) Fair Value & Analysis
Healthcare · PL · Market cap 5.8B PLN
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 186.23 PLN to 149.07 PLN (−20.0%) since Jun 23, 2026. Share price +0.9% over the past month.
Price vs Fair Value (12 months)
12‑month range 142.20 PLN – 208.20 PLN · fair‑value band 111.80 PLN – 242.10 PLN · the 172.50 PLN price screens above the 149.07 PLN fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Diagnostyka S.A (DIA) currently trades at 172.50 PLN, while our model-based Fair Value estimate is 149.07 PLN — implying the stock looks roughly 13.6% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Diagnostyka S.A generated revenue of 2.4B PLN at a net margin of 10.4%. Revenue grew 19.3% year over year. It earns a return on equity of 53.4%. Net debt stands at 615M PLN. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides services to individual clients, and public and private entities. Diagnostyka S.A. was founded in 1998 and is headquartered in Kraków, Poland.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Diagnostyka S.A reported revenue of 2.4B PLN in FY2025 versus 1.8B PLN in FY2021, a compound +6.9%/yr. Reported net income was 252M PLN in FY2025, compounding −18.0%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $482.04 | $202.02 | -58% |
| Danaher Corporation DHR | $178.97 | $112.34 | -37% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $61.97 | $14.23 | -77% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Diagnostyka S.A (DIA) undervalued?
What is the fair value of DIA?
What is the quality score of DIA?
What is the revenue of Diagnostyka S.A (DIA)?
What is the net profit margin of DIA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.